【摘要】 目的分析他汀类药联合替罗非班应用于冠心病经皮冠状动脉介入治疗(PCI)术后患者的临床疗效。方法 78例冠心病PCI术后患者,按数字随机表法分为对照组和治疗组,每组39例。对照组采用阿伐他汀治疗,治疗组在对照组基础上加服替罗非班治疗,比较两组治疗效果,治疗前后肌酸激酶同工酶(CK-MB)、超敏C反应蛋白(hs-CRP)水平及生活质量[躯体健康(PF)、躯体职能(RF)、躯体疼痛(BP)、总体健康(GH)、精力(VT)、社会功能(SF)、情绪角色职能(RE)和心理健康(MH)]评分。结果对照组中总有效率为61.5%,治疗组总有效率为89.7%;治疗组总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗前两组PF、 RF、BP、GH、VT、SF、RE和MH评分比较差异无统计学意义(P>0.05);治疗后治疗组PF、 RF、BP、GH、VT、SF、RE和MH评分高于对照组,差异有统计学意义(P<0.05)。治疗前两组CK-MB、hs-CRP水平比较差异无统计学意义(P>0.05);治疗后治疗组CK-MB(24.2±3.0)U/L、hs-CRP(2.2±0.5)mg/L明显低于对照组的(50.1±8.6)U/L、(5.4±0.7)mg/L,差异有统计学意义(P<0.05)。结论他汀类药物联合替罗非班用于冠心病PCI术后患者,其治疗效果明显,可更好地控制临床症状,显示治疗优越性。更多还原

【Abstract】 Objective To analyze the clinical efficacy of statins combined with tirofiban in patients with coronary heart disease after percutaneous coronary intervention(PCI). Methods A total of 78 coronary heart disease patients with PCI were divided by random number table method into control group and treatment group, with 39 cases in each group. The control group was treated with atorvastatin, and the treatment group was treated with tirofiban on the basis of the control group. Comparison were made on treatment effect, creatine kinase isoenzyme(CK-MB), high-sensitivity C-reactive protein(hs-CRP) levels, and quality of life [physical function(PF), role-physical(RP), body pain(BP), general health(GH), vitality(VT), social function(SF), role emotional(RE) and mental health(MH)] score before and after treatment between the two groups. Results The control group had total effective rate as 61.5%, which was 89.7% in the treatment group. The treatment group had obviously higher total effective rate than the control group, and the difference was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in PF, RF, BP, GH, VT, SF, RE and MH score(P>0.05). After treatment, the treatment group had higher PF, RF, BP, GH, VT, SF, RE and MH score than the control group, and the difference was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in CK-MB and hs-CRP(P>0.05). After treatment, the treatment group had obviously lower CK-MB as(24.2±3.0) U/L and hs-CRP as(2.2±0.5) mg/L than(50.1±8.6) U/L and(5.4±0.7) mg/L in the control group, and their difference was statistically significant(P<0.05). Conclusion Combination of statins and tirofiban shows obvious effect in patients with coronary heart disease after PCI, and it can better control the clinical symptoms and show the superiority of treatment.更多还原